Tight glycemic control does not affect asymmetric-dimethylarginine in septic patients
- 184 Downloads
We investigated whether preventing hyperglycemia in septic patients affected the plasma concentration of asymmetric-dimethylarginine and if this was associated with clinical benefit.
A prospective, multicenter, randomized, controlled, clinical study.
Intensive care units (ICU) in three university hospitals.
A total of 72 patients admitted for severe sepsis or septic shock, who stayed at least 3 days in the ICU. At admission the patients were assigned to receive either tight or conventional glycemic control.
Determination of circulating levels of asymmetric-dimethylarginine, arginine, interleukin-6, C-reactive-protein and tumor-necrosis-factor-α.
Measurements and results
Blood was sampled at admission (no differences between groups), and on the 3rd, 6th, 9th, and 12th (T12) days. Sequential organ failure assessment was scored at each sampling time. All the data were analyzed on an intention-to-treat basis. The control and treatment groups received the same energy intake, glycemia (110.4 ± 17.3 vs. 163.0 ± 28.9 mg/dL, P < 0.001) and insulin (P = 0.02) supply differed. No differences were found in high plasma levels of asymmetric-dimethylarginine (P = 0.812) at any time during the ICU stay. The clinical course, as indicated by markers of inflammation, average and maximum organ failure score, ICU stay and ICU and 90-day mortality, was the same.
Intensive insulin treatment, while achieving glucose control, did not reduce asymmetric-dimethylarginine in high-risk septic patients fed with no more than 25 kcal/kg per day to limit ventilatory demand and to simplify glucose control.
45 (SIRS/sepsis: clinical studies).
KeywordsADMA Sepsis Glycemic control Insulin therapy Endocrine
We thank Alberto Morabito, Professor of Medical Statistics, Università degli Studi di Milano, for the accurate revision of the statistical analysis of the study. We are grateful to J. D. Baggott for editing the English.
- 12.Schnabel R, Blankenberg S, Lubos E, Lackner KJ, Rupprecht HJ, Espinola-Klein C, Jachmann N, Post F, Peetz D, Bickel C, Cambien F, Tiret L, Münzel T (2005) Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 97:e53–e59PubMedCrossRefGoogle Scholar
- 15.Siroen MP, Van Leeuven PAM, Nijveldt RJ, Teerlink T, Wouters PJ, Van den Berghe G (2005) Modulation of asymmetric dimethylarginine in critically ill patients receiving intensive insulin treatment: a possible explanation of reduced morbidity and mortality? Crit Care Med 33:504–510PubMedCrossRefGoogle Scholar
- 16.O’Dwyer MJ, Dempsey F, Crowley V, Kelleher DP, McManus R, Ryan T (2006) Septic shock is correlated with asymmetrical dimethylarginine levels, which may be influenced by a polymorphism in the dimethylarginine dimethylaminohydrolase II gene: a prospective observational study. Crit Care 10:R139PubMedCrossRefGoogle Scholar
- 17.Maas R, Dentz L, Schwedhelm E, Thoms W, Kuss O, Hitmeyer N, Hdden M, Koss T, Standl T, Boger RH (2007) Elevated plasma concentrations of the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine predict adverse events in patients undergoing noncardiac surgery. Crit Care Med 35:1876–1881PubMedCrossRefGoogle Scholar
- 18.Zoccali C, Bode-Böger SM, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frölich J, Böger RH (2001) Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358:2113–2117PubMedCrossRefGoogle Scholar
- 33.Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natansori C, Loeffler M, Reinhart K, German Competence Network Sepsis (SepNet) (2008) Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 358:125–139PubMedCrossRefGoogle Scholar
- 34.Devos P, Preiser JC, Melot C (2007) Impact of tight glucose control by Intensive insulin therapy on ICU mortality and the rate of hypoglycaemia: final results of the Glucocontrol study. Intensive Care Med 33(Suppl 2):S189Google Scholar